Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting.
Adult
Anti-HIV Agents
/ therapeutic use
Bangladesh
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
/ cytology
CD8-Positive T-Lymphocytes
/ cytology
Cohort Studies
Female
HIV Infections
/ drug therapy
HIV-1
/ drug effects
Humans
Lymphocyte Count
Male
Middle Aged
Prevalence
Transgender Persons
/ statistics & numerical data
Treatment Outcome
Viral Load
/ drug effects
Young Adult
Bangladesh
HIV
first-line ART
high risk low prevalence
Journal
Journal of the International Association of Providers of AIDS Care
ISSN: 2325-9582
Titre abrégé: J Int Assoc Provid AIDS Care
Pays: United States
ID NLM: 101603896
Informations de publication
Date de publication:
Historique:
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
16
7
2020
Statut:
ppublish
Résumé
The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with CD4 T-cell count of <350 cells/µL (n = 33), and therapy receivers for >1 year prior to the study period (n = 34). Therapy initiators who continued the study (n = 20) were followed up after 12 and 24 weeks of therapy initiation. The CD4 and CD8 T-lymphocyte count estimation and (VL) were quantified. The mean CD4 T-lymphocyte count was significantly reduced among the therapy initiators in comparison to therapy naive and therapy receivers. Similar findings were observed for CD8 T-lymphocyte count among the study groups. The mean HIV-1 RNA VL among therapy initiators showed a significant decrease after 12 and 24 weeks, and 85% patients in this group obtained undetectable VL status indicating the good therapeutic outcome.
Identifiants
pubmed: 31392926
doi: 10.1177/2325958219867329
pmc: PMC6900579
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2325958219867329Références
Indian J Med Sci. 2007 Jul;61(7):390-7
pubmed: 17611344
HIV Med. 2005 May;6(3):198-205
pubmed: 15876287
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
Nepal Med Coll J. 2008 Mar;10(1):45-7
pubmed: 18700632
J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1147-54
pubmed: 15319674
Intern Med J. 2010 Apr;40(4):265-74
pubmed: 19460050
Top HIV Med. 2008 Aug-Sep;16(3):266-85
pubmed: 19856548
BMC Public Health. 2011 Feb 08;11:88
pubmed: 21303548
Indian J Med Res. 2006 Sep;124(3):319-30
pubmed: 17085836
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
Indian J Med Res. 2015 Jan;141(1):119-21
pubmed: 25857504
BMC Infect Dis. 2014 Jan 14;14:28
pubmed: 24422906
HIV Clin Trials. 2009 Mar-Apr;10(2):116-24
pubmed: 19487182
J Infect Dis. 2004 Apr 1;189(7):1199-208
pubmed: 15031788
HIV Med. 2006 Mar;7(2):99-104
pubmed: 16420254
J Int Assoc Physicians AIDS Care (Chic). 2011 Mar-Apr;10(2):97-104
pubmed: 21278365
J Prev Soc Med. 1999 Jun;18(1):74-83
pubmed: 12179659
Int J Infect Dis. 2019 Jun;83:109-115
pubmed: 30928433
Future Microbiol. 2011 Nov;6(11):1251-60
pubmed: 22082287
Nat Med. 1998 Feb;4(2):208-14
pubmed: 9461195
Indian J Med Microbiol. 2003 Oct-Dec;21(4):274-6
pubmed: 17643043
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):23-30
pubmed: 16340469